Navigation Links
OneStep PSA InstaTest

ProductsOneStep PSA InstaTest
Company Bio-Quant, Inc.
Item OneStep PSA InstaTest
Features 
  • Sensitivity of InstaTest PSA is 100%
  • Specificity is 98.5%
  • Results in 15 minutes
  • Description Prostate specific antigen (PSA) is a serine protease that is found only in the prostate within the epithelial cells of the acini and ducts. Normal PSA concentration in whole blood or serum is 0.1-2.6 ng/ml. Reports have suggested that elevated level of whole blood or serum PSA is the must useful tumor markers in diagnosis of prostate cancers. InstaTest PSA is designed to detect PSA concentration in whole blood or serum as low as 4 ng/ml within 15 minutes.

    There is one immunochromatographic testing device in a protected pouch with desiccant and one disposable sample dropper. A testing device is a test membrane with anti-PSA antibodies and conjugates in a stabilizing matrix containing proteins and sodium azide, enclosed in plastic casing.

    The result is read visually by observing the symbols developing in the test ("T") and control ("C") zones of the result window. Distinctive control line also serves as an indicator of proper performance of the test device. Comparative studies demonstrated that relative sensitivity of InstaTest PSA is 100%, and its relative specificity is 98.5%.

    Info Bio-Quant, Inc.
    Customer Service: (858) 450-0048
    Web site: http://www.bio-quant.com/

    Related medicine products :

    1. OneStep RapiDip Gonorrhea InstaTest
    2. OneStep Malaria (P.f /Vivax) RapiCard InstaTest
    ... on/off switch which allows user to stop rotor ... hinge, with stainless steel pin is virtually indestructible. ... Spins 6 microcentrifuge tubes at low to medium ... g. 6 inch x 6 inch footprint. Starts ...
    Inquire...
    Spectrafuge 16M High speed microcentrifuge. High g-force for molecular biology applications. Brushless, maintenance-free motor. Easy to use control panel. Complete with 18 x 1.5/2.0 ml rotor. StripSp...
    ... Powerful single rotation speed of 10,000 ... (x g) , Pellets single- and double-stranded ... and continuous spinning , 12-position rotor holds ... 1.5-ml microcentrifuge tubes , Replaceable rotor ...
    Medicine Products:
    (Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
    (Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
    (Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
    (Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
    (Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
    Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
    ... By Amanda Gardner HealthDay Reporter , MONDAY, July ... evidence proving that staying in shape and eating right are ... that over 8 million Americans have histories of heart attack, ... the message seriously. That,s the theme of a new ...
    ... about clinical trials for drugs that have been approved ... health risks, an independent committee at the Institute of ... has developed a conceptual framework to guide the agency ... drug-safety trials. The recommendations of the committee, requested ...
    ... Parkinson disease patients aren,t walking talls ... alleviated with drugs that target dompamine, a chemical in ... and therefore known as a neurotransmitter. However, such drugs ... commonly affect individuals with severe and advanced forms of ...
    ... Calif., July 12, 2010 UC Irvine public health ... in impoverished reaches of China, Myanmar and Thailand, thanks ... of a seven-year, $14.5 million award to Pennsylvania State ... Diseases. Yan will collaborate with Penn State principal investigator ...
    ... Drinking tart cherry juice daily could help reduce the severity ... according to a new study published in the Journal ... University of Pennsylvania, University of Rochester and VA Center of ... of 15 older adults. The adults drank 8 ounces of ...
    ... that roams with only limited control among the rural poor ... cruzi is the triatomine insect, or "kissing bug," which thrives ... sucks the blood of mammals, helping T. cruzi ... to lie on porches or other areas easily accessible to ...
    Cached Medicine News:Health News:Lifestyle Interventions Needed to Stay Heart-Healthy 2Health News:Lifestyle Interventions Needed to Stay Heart-Healthy 3Health News:Hopkins faculty lead development of report to FDA on ethical, scientific issues related to 'post-market' clinical trials 2Health News:Hopkins faculty lead development of report to FDA on ethical, scientific issues related to 'post-market' clinical trials 3Health News:JCI online early table of contents: July 12, 2010 2Health News:JCI online early table of contents: July 12, 2010 3Health News:JCI online early table of contents: July 12, 2010 4Health News:JCI online early table of contents: July 12, 2010 5Health News:JCI online early table of contents: July 12, 2010 6Health News:JCI online early table of contents: July 12, 2010 7Health News:JCI online early table of contents: July 12, 2010 8Health News:New study suggests tart cherry juice can be a natural solution for insomnia 2Health News:Dogs may help collar Chagas disease 2
    (Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
    (Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
    (Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
    Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3